Literature DB >> 28705810

The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region.

Khiem Nguyen1, Jin Li1, Robbins Puthenveetil2, Xiaochen Lin1, Michael M Poe1, Chia-Hung Christine Hsiao1, Olga Vinogradova1, Andrew J Wiemer3,4.   

Abstract

Small isoprenoid diphosphates, such as (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate (HMBPP), are ligands of the internal domain of BTN3A1. Ligand binding in target cells promotes activation of Vγ9Vδ2 T cells. We demonstrate by small-angle X-ray scattering (SAXS) that HMBPP binding to the internal domain of BTN3A1 induces a conformational change in the position of the B30.2 domain relative to the juxtamembrane (JM) region. To better understand the molecular details of this conformational rearrangement, NMR spectroscopy was used to discover that the JM region interacts with HMBPP, specifically at the diphosphate. The spectral location of the affected amide peaks, partial NMR assignments, and JM mutants (ST296AA or T304A) investigated, confirm that the backbone amide of at least one Thr (Thr304), adjacent to conserved Ser, comes close to the HMBPP diphosphate, whereas double mutation of nonconserved residues (Ser/Thr296/297) may perturb the local fold. Cellular mutation of either of the identified Thr residues reduces the activation of Vγ9Vδ2 T cells by HMBPP, zoledronate, and POM2-C-HMBP, but not by a partial agonist BTN3 antibody. Taken together, our results show that ligand binding to BTN3A1 induces a conformational change within the intracellular domain that involves the JM region and is required for full activation.-Nguyen, K., Li, J., Puthenveetil, R., Lin, X., Poe, M. M., Hsiao, C.-H. C., Vinogradova, O., Wiemer, A. J. The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region. © FASEB.

Entities:  

Keywords:  B7 family coreceptor; CD277; bisphosphonate; phosphoantigen; γ δ T cell

Mesh:

Substances:

Year:  2017        PMID: 28705810      PMCID: PMC5636706          DOI: 10.1096/fj.201601370RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  44 in total

Review 1.  Analysis of X-ray and neutron scattering from biomacromolecular solutions.

Authors:  Maxim V Petoukhov; Dmitri I Svergun
Journal:  Curr Opin Struct Biol       Date:  2007-08-21       Impact factor: 6.809

2.  HMBPP Analog Prodrugs Bypass Energy-Dependent Uptake To Promote Efficient BTN3A1-Mediated Malignant Cell Lysis by Vγ9Vδ2 T Lymphocyte Effectors.

Authors:  Ashley M Kilcollins; Jin Li; Chia-Hung Christine Hsiao; Andrew J Wiemer
Journal:  J Immunol       Date:  2016-06-06       Impact factor: 5.422

Review 3.  Human gamma delta T cells: Evolution and ligand recognition.

Authors:  Erin J Adams; Siyi Gu; Adrienne M Luoma
Journal:  Cell Immunol       Date:  2015-05-06       Impact factor: 4.868

4.  Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.

Authors:  Thibault Santolaria; Myriam Robard; Alexandra Léger; Véronique Catros; Marc Bonneville; Emmanuel Scotet
Journal:  J Immunol       Date:  2013-07-08       Impact factor: 5.422

5.  Nanodiscs and Solution NMR: preparation, application and challenges.

Authors:  Robbins Puthenveetil; Khiem Nguyen; Olga Vinogradova
Journal:  Nanotechnol Rev       Date:  2016-12-15       Impact factor: 7.848

6.  Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset.

Authors:  Christelle Harly; Yves Guillaume; Steven Nedellec; Cassie-Marie Peigné; Hannu Mönkkönen; Jukka Mönkkönen; Jianqiang Li; Jürgen Kuball; Erin J Adams; Sonia Netzer; Julie Déchanet-Merville; Alexandra Léger; Thomas Herrmann; Richard Breathnach; Daniel Olive; Marc Bonneville; Emmanuel Scotet
Journal:  Blood       Date:  2012-07-05       Impact factor: 22.113

Review 7.  What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Authors:  Jean-Jacques Fournié; Hélène Sicard; Mary Poupot; Christine Bezombes; Amandine Blanc; François Romagné; Loic Ysebaert; Guy Laurent
Journal:  Cell Mol Immunol       Date:  2012-12-17       Impact factor: 11.530

8.  Vγ9Vδ2 TCR-activation by phosphorylated antigens requires butyrophilin 3 A1 (BTN3A1) and additional genes on human chromosome 6.

Authors:  Felipe Riaño; Mohindar M Karunakaran; Lisa Starick; Jianqiang Li; Claus J Scholz; Volker Kunzmann; Daniel Olive; Sabine Amslinger; Thomas Herrmann
Journal:  Eur J Immunol       Date:  2014-06-30       Impact factor: 5.532

9.  Replacing the pyrophosphate group of HMB-PP by a diphosphonate function abrogates Its potential to activate human gammadelta T cells but does not lead to competitive antagonism.

Authors:  Armin Reichenberg; Martin Hintz; Yvonne Kletschek; Tanja Kuhl; Christian Haug; Rosel Engel; Jens Moll; Dmitry N Ostrovsky; Hassan Jomaa; Matthias Eberl
Journal:  Bioorg Med Chem Lett       Date:  2003-04-07       Impact factor: 2.823

10.  RhoB Mediates Phosphoantigen Recognition by Vγ9Vδ2 T Cell Receptor.

Authors:  Zsolt Sebestyen; Wouter Scheper; Anna Vyborova; Siyi Gu; Zuzana Rychnavska; Marleen Schiffler; Astrid Cleven; Coraline Chéneau; Martje van Noorden; Cassie-Marie Peigné; Daniel Olive; Robert Jan Lebbink; Rimke Oostvogels; Tuna Mutis; Gerrit Jan Schuurhuis; Erin J Adams; Emmanuel Scotet; Jürgen Kuball
Journal:  Cell Rep       Date:  2016-05-19       Impact factor: 9.423

View more
  26 in total

1.  A power law function describes the time- and dose-dependency of Vγ9Vδ2 T cell activation by phosphoantigens.

Authors:  Chia-Hung Christine Hsiao; Andrew J Wiemer
Journal:  Biochem Pharmacol       Date:  2018-11-02       Impact factor: 5.858

2.  Critical Roles for Coiled-Coil Dimers of Butyrophilin 3A1 in the Sensing of Prenyl Pyrophosphates by Human Vγ2Vδ2 T Cells.

Authors:  Hong Wang; Mohanad H Nada; Yoshimasa Tanaka; Shun Sakuraba; Craig T Morita
Journal:  J Immunol       Date:  2019-06-21       Impact factor: 5.422

3.  Stability and Efficiency of Mixed Aryl Phosphonate Prodrugs.

Authors:  Benjamin J Foust; Jin Li; Chia-Hung Christine Hsiao; David F Wiemer; Andrew J Wiemer
Journal:  ChemMedChem       Date:  2019-07-24       Impact factor: 3.466

4.  Alpaca (Vicugna pacos), the first nonprimate species with a phosphoantigen-reactive Vγ9Vδ2 T cell subset.

Authors:  Alina S Fichtner; Mohindar M Karunakaran; Siyi Gu; Christopher T Boughter; Marta T Borowska; Lisa Starick; Anna Nöhren; Thomas W Göbel; Erin J Adams; Thomas Herrmann
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-05       Impact factor: 11.205

Review 5.  Structure-Activity Relationships of Butyrophilin 3 Ligands.

Authors:  Andrew J Wiemer
Journal:  ChemMedChem       Date:  2020-05-26       Impact factor: 3.466

6.  Synthesis and Metabolism of BTN3A1 Ligands: Studies on Diene Modifications to the Phosphoantigen Scaffold.

Authors:  Nyema M Harmon; Michael M Poe; Xueting Huang; Rohit Singh; Benjamin J Foust; Chia-Hung Christine Hsiao; David F Wiemer; Andrew J Wiemer
Journal:  ACS Med Chem Lett       Date:  2022-01-27       Impact factor: 4.345

Review 7.  Butyrophilin3A proteins and Vγ9Vδ2 T cell activation.

Authors:  Siyi Gu; Marta T Borowska; Christopher T Boughter; Erin J Adams
Journal:  Semin Cell Dev Biol       Date:  2018-03-09       Impact factor: 7.727

8.  A luciferase lysis assay reveals in vivo malignant cell sensitization by phosphoantigen prodrugs.

Authors:  Jin Li; Nicholas A Lentini; David F Wiemer; Andrew J Wiemer
Journal:  Biochem Pharmacol       Date:  2019-10-16       Impact factor: 5.858

9.  Synthesis and Metabolism of BTN3A1 Ligands: Studies on Modifications of the Allylic Alcohol.

Authors:  Nicholas A Lentini; Chloe M Schroeder; Nyema M Harmon; Xueting Huang; Megan A Schladetsch; Benjamin J Foust; Michael M Poe; Chia-Hung Christine Hsiao; Andrew J Wiemer; David F Wiemer
Journal:  ACS Med Chem Lett       Date:  2020-12-04       Impact factor: 4.345

Review 10.  Prognostic and Therapeutic Significance of BTN3A Proteins in Tumors.

Authors:  Sihan Chen; Zhangyun Li; Wenyi Huang; Yanyan Wang; Shaohua Fan
Journal:  J Cancer       Date:  2021-05-27       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.